Edited on October 30, 2026
Mycoplasma genitalium lacks a cell wall; this is a biological characteristic and is not the same as acquired antibiotic resistance. Both factors are important for treatment. Therefore, targeted pathogen detection can be combined with a resistance test before selecting a treatment. [1][2]
As Herbert Eder, I will explain why this level of precision is also essential in frequency therapy. Unusual pathogen biology does not in itself make an alternative claim of efficacy plausible or clinically proven.
What Makes Mycoplasma genitalium Biologically Unique
M. genitalium lacks a cell wall. Antibiotics that interfere with the formation of a bacterial cell wall—such as penicillins—are therefore ineffective against this organism. The British surveillance report MARS also describes its small genome and limited therapeutic targets. Added to this are acquired resistances to drugs that would otherwise be suitable for treatment. The absence of a cell wall and newly developed resistance are thus different reasons for the limited choice of medications. [1]
The term „bacteria“ alone does not imply a specific treatment. Ask your doctor to explain which active ingredient is appropriate for the identified pathogen and why, if necessary, multiple treatment steps may be required. An antibiotic that helped with a previous, different infection is not automatically the right choice.
How the infection is transmitted
The European guideline describes transmission through direct mucosal contact. M. genitalium can be transmitted sexually, even if a person does not notice any obvious symptoms. Ongoing sexual contact is particularly relevant, as it allows for repeated transmission between partners. However, detection of the pathogen does not provide a reliable timeline that would allow the exact date of infection to be determined. [2]
This distinction is important when having conversations within a relationship. Medical information should first be used to coordinate testing and treatment. No definitive conclusions about another person’s behavior or the source of the infection should be drawn from a single lab result. A sexual health counseling center can provide support during difficult conversations.
What symptoms and conditions are associated with this?
The Australian STI guidelines classify M. genitalium as a cause of urethritis, cervicitis, and pelvic inflammatory disease. Links to other complications, such as fallopian tube-related infertility or proctitis, are less clear-cut and are not consistently demonstrated across all studies. Therefore, there is no justification for attributing every chronic organ problem to this bacterium. [3]
Possible symptoms include pain when urinating, unusual discharge, lower abdominal pain, and bleeding between periods or after sexual intercourse. Many people do not notice any symptoms. Symptoms may also subside even though the infection is still present. The Scottish health portal NHS inform recommends seeking evaluation at an appropriate medical facility if you experience any of these symptoms. [4]
During the examination, describe as specifically as possible what has changed. Information about the onset, progression, pain, and medications you have already taken is more helpful than assuming that all your symptoms must have a single, rare cause. The medical evaluation should also consider other plausible explanations.
Why Targeted Testing Makes More Sense Than a Broad-Based Testing Package
The final 2025 British BASHH guideline does not recommend routine screening for M. genitalium in asymptomatic individuals. The decision to test is based on specific clinical presentations and risk factors. Recent sexual contacts of a person confirmed to be infected should be considered separately. A nonspecific multi-pathogen panel for asymptomatic individuals therefore does not automatically confer a health benefit. [5]
Finding more information does not always lead to greater clarity. Before undergoing a test, you should discuss what a positive or negative result would mean for you. A sound decision about testing links a specific question to an appropriate procedure and a sensible next step. Without this context, an incidental finding can create additional uncertainty.
How the pathogen is detected
Nucleic acid amplification tests (NAATs) are used for routine diagnostics. They detect specific genetic material. Culture is unsuitable for practical diagnostics due to the extremely slow growth rate. The European guideline also emphasizes testing for mutations associated with macrolide resistance. This allows the test to go beyond mere pathogen detection and contribute to treatment selection. [2]
The Melbourne Sexual Health Center specifies the appropriate samples based on the body site: For a urethral infection, the first-void urine sample can be used; for vaginal or cervical issues, the appropriate swabs are required. A vaginal swab is more sensitive than a urine sample in this context. Therefore, you should clarify with the testing facility which sample is required. [6]
A routine urinalysis is not the same as a specific Mgen test. Therefore, when receiving test results, ask about the exact method used and the sample analyzed. If a commercial service claims an infection without providing verifiable evidence of the pathogen, they should explain how this diagnosis can be confirmed.
What Resistance-Based Treatment Means
The Australian guidelines describe a sequential treatment approach: First, doxycycline can reduce the bacterial load; subsequently, the choice of the next active ingredient depends on the resistance profile. A different approach is warranted for macrolide susceptibility than for macrolide resistance. In cases of difficult infections or those that have repeatedly failed treatment, consultation with a specialist is important. The decision also takes into account contraindications, drug interactions, and potential side effects. [3]
Such a plan is not a recommendation to combine antibiotics on your own. Please bring the names, duration, and as precise a timeline as possible for previous treatments. It is particularly helpful to know whether symptoms disappeared during treatment, remained unchanged, or returned later. This allows us to understand the situation so far before simply adding another active ingredient.
What a clinical study revealed about treatment strategies
Durukan and colleagues investigated a resistance-based strategy in 383 individuals at the Melbourne Sexual Health Center. Following treatment with doxycycline, susceptible infections were treated with azithromycin and resistant infections with moxifloxacin. Microbiological cure rates in the evaluated study were 95.4 percent and 92.0 percent, respectively. This was a cohort study and does not constitute a guarantee of success for every individual. New macrolide resistance was also observed. [7]
Such results support a structured approach, but must be considered in light of local resistance patterns and individual circumstances. A percentage from a single facility is not a personal guarantee. The key factors remain whether the treatment protocol used there is appropriate for your condition and what steps will be taken if there is no improvement.
Why Side Effects Must Be Discussed When Making a Choice
The British Medicines and Healthcare products Regulatory Agency (MHRA) has further restricted the systemic use of fluoroquinolones due to potential long-lasting or irreversible side effects. These effects may affect, among other things, tendons, muscles, joints, nerves, and mental functions. The agency emphasizes the need for careful selection when other suitable antibiotics are not an option. Moxifloxacin belongs to this class of drugs; its use therefore requires an individualized benefit-risk assessment. [8]
Before a prescription is issued, report any previous intolerances and all medications you take regularly. Ask about specific warning signs and the agreed-upon course of action should they occur. Such a discussion is intended to facilitate and support necessary treatment, not to be replaced by fear or by the assumption that every alternative option is automatically safe.
Review: Why Guidelines Offer Different Recommendations
The 2025 BASHH guideline no longer requires a follow-up test for all affected individuals once symptoms have subsided. A follow-up test may be performed if symptoms persist and a persistent infection is suspected. The 2021 European guideline is broader in scope: It recommends considering a follow-up test for all affected individuals and taking the sample no earlier than three weeks after the end of treatment. [5], [2]
These differences should be clearly explained during the treatment consultation. Ask what guidelines your healthcare provider follows, why a follow-up visit with them is recommended, and when it should take place. A test taken immediately after taking the last pill does not automatically provide the same information as a scheduled follow-up test. Agree on the procedure rather than trying to piece together a new schedule yourself based on various information found online.
Take sexual contact and re-transmission into account
The Melbourne Sexual Health Center recommends that infected partners be tested and treated, especially in an ongoing relationship. If symptoms persist or recur, both the possibility of treatment failure due to resistance and the possibility of reinfection must be considered. Treatment and contact management are therefore interrelated. [6]
Clarify for how long sexual contact should be suspended or what protective measures should be followed. The recommendation should align with the prescribed treatment and the scheduled follow-up appointment. A partner should not simply share your medication but should receive their own evaluation. If it is difficult to inform your partner, discuss this confidentially with your doctor.
Plan for pregnancy and special situations separately
If you are pregnant, breastfeeding, or might be pregnant, please inform your doctor before each prescription. Be sure to ask how this situation affects your treatment plan and whether specialized counseling is necessary. Do not rely on a previous self-prescription or a treatment plan found on a forum. This also applies if you have undergone several unsuccessful treatments or are experiencing symptoms that are difficult to diagnose.
Frequency data do not constitute evidence of effective treatment
Certain kilohertz ranges are assigned to the bacterium in frequency lists. However, such numerical data does not yet reflect a verifiable clinical study: It does not specify the method used to detect the pathogen, the control group that was treated, or whether those affected were reliably cured as a result. The necessary intermediate steps for a therapeutic recommendation are therefore missing.
If you are presented with such an offer, ask to see which study specifically tested this pathogen and its specific application in humans. Changes in well-being and confirmed detection of the pathogen are two different outcomes. A complementary treatment should therefore not lead to the postponement of a medically justified diagnosis, couples counseling, or necessary treatment.
Questions You Can Bring to Your Results Discussion
Ask about the area of the body that was examined, the resistance test, the reasons for the choice of medication, and the next step in your follow-up care. Also, make a note of how your current sexual partners are being involved and who you can contact if you develop new symptoms. A clear, jointly discussed plan is more helpful than constantly trying new treatments without a clear goal.
Mycoplasma genitalium and Frequency Therapy: Resistance Is Not Evidence of Efficacy
When suitable antibiotics are only available to a limited extent, there is a growing demand for alternative solutions. However, this gap in care does not provide evidence in favor of a screening program. Such a program would need to be tested in people with confirmed infections, including assessment of resistance status, reinfection, and appropriately scheduled follow-up care. [2][3][5]
The resistance-oriented treatment cohort studied describes a drug treatment strategy. Its cure rates should not be applied to a frequency device nor used as a personal guarantee. My classification therefore distinguishes between a technical program designation and a microbiologically confirmed treatment outcome. [7]
Related in-depth study in the subject area of frequency therapy and health education: Infectious Diseases and Diagnostic Classification · Evaluating Clinical Studies on Frequency Therapy.
Sources and Further Information
- UK Health Security Agency: 2024 MARS Report on Mycoplasma genitalium and Antibiotic Resistance. Retrieved October 29, 2026.
- Jensen et al.: European Guidelines on Mycoplasma genitalium 2021, published in 2022. Retrieved October 29, 2026.
- Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine: Mycoplasma genitalium. Retrieved October 29, 2026.
- NHS inform: Mycoplasma genitalium, Patient Information. Retrieved October 29, 2026.
- BASHH: National Guidelines for the Management of Mycoplasma genitalium Infection, Final Version 2025. Retrieved October 29, 2026.
- Melbourne Sexual Health Center: Mycoplasma genitalium Treatment Guidelines. Retrieved October 29, 2026.
- Durukan et al. 2020: Resistance-Guided Antimicrobial Therapy Using Doxycycline-Moxifloxacin and Doxycycline-Azithromycin. Retrieved October 29, 2026.
- MHRA: New Restrictions on Fluoroquinolone Antibiotics, January 2024. Retrieved October 29, 2026.
Topic Overview: Pathogen Knowledge.
Comments are closed, but trackbacks and pingbacks are open.